[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 455
Citations 0
Comment & Response
September 24, 2014

PET Screening for Metastatic Colorectal Adenocarcinoma

Author Affiliations
  • 1Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
  • 2Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
JAMA. 2014;312(12):1255-1256. doi:10.1001/jama.2014.9850

To the Editor We dispute the conclusion that fluorodeoxyglucose (FDG) PET-CT is of questionable value to patients with hepatic metastases from colorectal cancer being evaluated for curative intent surgery.1 When current best surgical practice infrequently leads to cure and has associated morbidity and cost, is a 9% improvement in surgical management of questionable value to patients?

First Page Preview View Large
First page PDF preview
First page PDF preview
×